Fatih Alasan

Dr. Fatih Alasan

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2015 in Tobacco Induced Diseases
Verified
Journal Article
Open access
CSCemil Isik Sonmez
Cemil Isik Sonmez
LALeyla Yilmaz Aydin
Leyla Yilmaz Aydin
YTYasemin Turker
Yasemin Turker
DBDavut Baltaci
Davut Baltaci
SDSuber Dikici
Suber Dikici
MDMustafa Demir
Mustafa Demir
Background: Primary care providers are uniquely positioned to initiate smoking cessation. We aimed to evaluate knowledge levels about the health effects of smoking and attitudes toward smoking and tobacco control activities among primary care providers. Methods: In the cross-sectional and...

7 February 2022 in Journal of Turkish Sleep Medicine
Verified
Journal Article
Closed access
OTOzge Oral Tapan
Ozge Oral Tapan
UTUtku Tapan
Utku Tapan
Fatih AlasanFatih Alasan
Fatih Alasan
AAAyşe Ferhan Akgül
Ayşe Ferhan Akgül
SGSebahat Genç
Sebahat Genç

16 October 2019 in The Aging Male
Verified
Journal Article
Closed access
Fatih AlasanFatih Alasan
Fatih Alasan
EBEge Güleç Balbay
Ege Güleç Balbay
ŞCŞengül Cangür
Şengül Cangür
ÖBÖner Balbay
Öner Balbay
LALeyla Yılmaz Aydın
Leyla Yılmaz Aydın
AAAli Nihat Annakkaya
Ali Nihat Annakkaya
Introduction: The aim of this study was to present the follow-up results of 110 patients who were given anti-tumor necrosis factor alpha (TNF-α) therapy for rheumatic and dermatologic diseases in a country with a high rates of active and latent tuberculosis bacillus infection. Material and Methods: Between February 2008 and January 2015, 110 cases in the age range of 23–77 who are using anti-TNF-α were included in the study retro-prospectively. Results: 52.7% of them (n = 58) were male. The most common diagnoses were rheumatoid arthritis (42.7%) and ankylosing spondylitis (38.2%). Most frequently given treatment were infliximab 37.3% and etanercept 30.9%, respectively. The 65 patients whose first tuberculin skin test (TST) value “5 mm and above” was started daily 300 mg INH prophylaxis for 9 months but 3 patients had not been started because of refusing treatment. In only one case chemoprophylaxis has had to be interrupted because of high liver function test due to the INH prophylaxis. TST conversion was observed in 14 patients. Further follow-up, it was observed that 4 patients had TST's positivity. Isoniazide (INH) prophylaxis was started these 18 patients (42.9%). Although INH prophylaxis has been given in two patients, they developed active tuberculosis in follow-up. Conclusion: Considering the INH resistance in our country, all patients especially the ones with residual lesion and history of previous exposure, should be followed up closely during the anti-TNF-α treatment.

15 September 2014
Verified
Journal Article
Closed access
YTYasemin Turker
Yasemin Turker
LALeyla Yilmaz Aydin
Leyla Yilmaz Aydin
DBDavut Baltaci
Davut Baltaci
OEOzgur Erdem
Ozgur Erdem
MTMehmet Halis Tanriverdi
Mehmet Halis Tanriverdi
Fatih AlasanFatih Alasan
Fatih Alasan

7 June 2021 in Monaldi Archives for Chest Disease
Verified
Journal Article
Open access
PDF file
EDEmrah Dogan
Emrah Dogan
UTUtku Tapan
Utku Tapan
OTOzge Oral Tapan
Ozge Oral Tapan
Fatih AlasanFatih Alasan
Fatih Alasan
Sabri Serhan OlcaySabri Serhan Olcay
Sabri Serhan Olcay
TOTuğba Çınar Olcay
Tuğba Çınar Olcay
The new UK strain was first described in December 2020. It was seen for the first time in Turkey in February 2021. It is not yet known whether the new strain has different CT patterns compared to the classical type. We present a 68-years-old male patient with an atypical CT presentation in which GGOs are gathered around the areas of paraseptal emphysema accompanied by CT and clinical findings. This involvement is an unexpected pattern because of the atypical distribution of the GGO.

1 December 2016
Verified
Journal Article
Closed access
DBDavut Baltaci
Davut Baltaci
LALeyla Yilmaz Aydin
Leyla Yilmaz Aydin
Fatih AlasanFatih Alasan
Fatih Alasan
MDMehmet Harun Deler
Mehmet Harun Deler
MKMehmet Serkan Karacam
Mehmet Serkan Karacam
FSFeyza Sariguzel
Feyza Sariguzel